Treatment of slow-channel congenital myasthenic syndrome with fluoxetine

C. Michel Harper, Takayasu Fukodome, Andrew G Engel

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The authors found that fluoxetine significantly shortens at 5 μM/L and nearly normalizes at 10 μM/L the prolonged opening bursts of slow-channel congenital myasthenic syndrome (SCCMS) acetylcholine receptors (AChR) expressed in fibroblasts. Prompted by this observation, they treated two SCCMS patients allergic to quinidine with up to 80 to 120 mg of fluoxetine per day over 3 years (serum fluoxetine + norfluoxetine levels 8 to 11 μM/L). Both patients showed marked subjective and objective improvement by quantitative muscle strength testing and electromyography.

Original languageEnglish (US)
Pages (from-to)1710-1713
Number of pages4
JournalNeurology
Volume60
Issue number10
StatePublished - May 27 2003

Fingerprint

Congenital Myasthenic Syndromes
Fluoxetine
Quinidine
Muscle Strength
Electromyography
Cholinergic Receptors
Therapeutics
Fibroblasts
Serum

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. / Harper, C. Michel; Fukodome, Takayasu; Engel, Andrew G.

In: Neurology, Vol. 60, No. 10, 27.05.2003, p. 1710-1713.

Research output: Contribution to journalArticle

Harper, CM, Fukodome, T & Engel, AG 2003, 'Treatment of slow-channel congenital myasthenic syndrome with fluoxetine', Neurology, vol. 60, no. 10, pp. 1710-1713.
Harper, C. Michel ; Fukodome, Takayasu ; Engel, Andrew G. / Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. In: Neurology. 2003 ; Vol. 60, No. 10. pp. 1710-1713.
@article{5f106077ce824e75938fdc654062cb9d,
title = "Treatment of slow-channel congenital myasthenic syndrome with fluoxetine",
abstract = "The authors found that fluoxetine significantly shortens at 5 μM/L and nearly normalizes at 10 μM/L the prolonged opening bursts of slow-channel congenital myasthenic syndrome (SCCMS) acetylcholine receptors (AChR) expressed in fibroblasts. Prompted by this observation, they treated two SCCMS patients allergic to quinidine with up to 80 to 120 mg of fluoxetine per day over 3 years (serum fluoxetine + norfluoxetine levels 8 to 11 μM/L). Both patients showed marked subjective and objective improvement by quantitative muscle strength testing and electromyography.",
author = "Harper, {C. Michel} and Takayasu Fukodome and Engel, {Andrew G}",
year = "2003",
month = "5",
day = "27",
language = "English (US)",
volume = "60",
pages = "1710--1713",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Treatment of slow-channel congenital myasthenic syndrome with fluoxetine

AU - Harper, C. Michel

AU - Fukodome, Takayasu

AU - Engel, Andrew G

PY - 2003/5/27

Y1 - 2003/5/27

N2 - The authors found that fluoxetine significantly shortens at 5 μM/L and nearly normalizes at 10 μM/L the prolonged opening bursts of slow-channel congenital myasthenic syndrome (SCCMS) acetylcholine receptors (AChR) expressed in fibroblasts. Prompted by this observation, they treated two SCCMS patients allergic to quinidine with up to 80 to 120 mg of fluoxetine per day over 3 years (serum fluoxetine + norfluoxetine levels 8 to 11 μM/L). Both patients showed marked subjective and objective improvement by quantitative muscle strength testing and electromyography.

AB - The authors found that fluoxetine significantly shortens at 5 μM/L and nearly normalizes at 10 μM/L the prolonged opening bursts of slow-channel congenital myasthenic syndrome (SCCMS) acetylcholine receptors (AChR) expressed in fibroblasts. Prompted by this observation, they treated two SCCMS patients allergic to quinidine with up to 80 to 120 mg of fluoxetine per day over 3 years (serum fluoxetine + norfluoxetine levels 8 to 11 μM/L). Both patients showed marked subjective and objective improvement by quantitative muscle strength testing and electromyography.

UR - http://www.scopus.com/inward/record.url?scp=0038476135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038476135&partnerID=8YFLogxK

M3 - Article

C2 - 12771277

AN - SCOPUS:0038476135

VL - 60

SP - 1710

EP - 1713

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -